Literature DB >> 9558102

Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis.

A Sjölander1, T M Baldwin, J M Curtis, E Handman.   

Abstract

Experimental systems based on immunization with plasmid DNA or immune-stimulating complexes were used to delineate the requirements for generation of protective immunity against murine leishmaniasis. Vaccination with plasmid DNA encoding the host-protective Leishmania major parasite surface Ag-2 primed for an essentially exclusive Th1 response that protected mice against L. major infection. In contrast, parasite surface Ag-2 in immune-stimulating complexes generated an immune response with mixed Th1-like and Th2-like properties that was not protective despite the activation of large numbers of CD4+ T cells secreting IFN-gamma. These results indicate that a Th1 response is sufficient to protect against cutaneous leishmaniasis, but the induction of a simultaneous Th2 response abrogates the Th1 effector function. DNA vaccines may therefore have an advantage for diseases in which protection depends on the induction of Th1 responses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9558102

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  39 in total

1.  Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.

Authors:  P C Melby; J Yang; W Zhao; L E Perez; J Cheng
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  A novel Leishmania infantum recombinant antigen which elicits interleukin 10 production by peripheral blood mononuclear cells of patients with visceral leishmaniasis.

Authors:  I Suffia; B Ferrua; X Stien; B Mograbi; P Marty; D Rousseau; K Fragaki; J Kubar
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.

Authors:  Salvador Iborra; Javier Carrión; Charles Anderson; Carlos Alonso; David Sacks; Manuel Soto
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  Identification of Leishmania donovani antigens stimulating cellular immune responses in exposed immune individuals.

Authors:  P Tripathi; S Ray; S Sunder; A Dube; S Naik
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

5.  A new multi-epitope peptide vaccine induces immune responses and protection against Leishmania infantum in BALB/c mice.

Authors:  Bahareh Vakili; Navid Nezafat; Bijan Zare; Nasrollah Erfani; Maryam Akbari; Younes Ghasemi; Mohammad Reza Rahbar; Gholam Reza Hatam
Journal:  Med Microbiol Immunol       Date:  2019-11-06       Impact factor: 3.402

6.  Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major.

Authors:  Javier Cote-Sierra; Amin Bredan; Carmen M Toldos; Benoit Stijlemans; Lea Brys; Pierre Cornelis; Manuel Segovia; Patrick de Baetselier; Hilde Revets
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

7.  Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability.

Authors:  Susana Mendez; Khaled Tabbara; Yasmine Belkaid; Sylvie Bertholet; Daniela Verthelyi; Dennis Klinman; Robert A Seder; David L Sacks
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

8.  Leishmaniasis Vaccine: Where are We Today?

Authors:  Lukasz Kedzierski
Journal:  J Glob Infect Dis       Date:  2010-05

9.  DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous Leishmaniasis.

Authors:  Kimberly Campbell; Hong Diao; Jiaxiang Ji; Lynn Soong
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

10.  The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice.

Authors:  Salvador Iborra; Manuel Soto; Javier Carrión; Ana Nieto; Edgar Fernández; Carlos Alonso; Jose M Requena
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.